Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: RETRACTED ARTICLE: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway

Fig. 6

AMPK–MFN2 signaling pathway is modulated by LATS2 overexpression. a–c Western blotting was performed to analyze the expression of p-AMPK and MFN2. Compound C (CC) was added to inhibit the activation of AMPK. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. d LDH release assay was used to determined cell death in response to AMPK inhibition. e ATP production was determined to reflect mitochondrial function in response to AMPK inhibition and/or LATS2 overexpression. f, g Immunofluorescence assay for cyt-c. The expression of nuclear cyt-c was measured. Compound C (CC) was added to inhibit the activation of AMPK. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us